1-Tert-butyl-3-propan-2-ylpiperidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Tert-butyl-3-propan-2-ylpiperidine
• 英文别名: 1-tert-butyl-3-propan-2-ylpiperidine
• 化学式: C₁₂H₂₅N
• 分子量: 183.33
• InChiKey: DKWBRGUFVJWCJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) DEGRADATION COMPOUNDS AND METHODS OF USE
  申请人：Icahn School of Medicine at Mount Sinai

  公开号：US20210395244A1

  公开（公告）日：2021-12-23

  This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such heterobifunctional compounds.

  该披露涉及异双功能化合物（例如，双功能小分子化合物），包含一种或多种异双功能化合物的组合物，以及使用这些异双功能化合物治疗患有某种疾病的受试者的方法。该披露还涉及用于识别此类异双功能化合物的方法。
• Substituted Pyrazole Derivatives As Selective CDK12/13 Inhibitors
  申请人：Aurigene Discovery Technologies Limited

  公开号：US20190308951A1

  公开（公告）日：2019-10-10

  The present invention provides substituted pyrazole derivatives of formula (I) which are therapeutically useful as selective CDK12/13 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or disorders associated with CDK12/13 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions with at least one of the substituted pyrazole derivatives of formula (I) or a pharmaceutically acceptable salt, an N-oxide or a stereoisomer thereof.

  本发明提供了公式（I）的取代吡唑衍生物，其在治疗上具有选择性CDK12/13抑制剂的治疗作用。这些化合物在哺乳动物中用于治疗和/或预防与CDK12/13相关的疾病和/或疾病。本发明还提供了这些化合物的制备以及含有公式（I）的至少一种取代吡唑衍生物或其药学上可接受的盐、N-氧化物或立体异构体的药物组合物。
• PURINONE COMPOUNDS AS KINASE INHIBITORS
  申请人：Pharmacyclics, Inc.

  公开号：US20140378446A1

  公开（公告）日：2014-12-25

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了一些与布鲁顿酪氨酸激酶（Btk）形成共价键的化合物。还描述了Btk的不可逆抑制剂。此外，还描述了Btk的可逆抑制剂。还披露了包括这些化合物的制药组合物。披露了使用Btk抑制剂的方法，单独或与其他治疗剂联合使用，用于治疗自身免疫疾病或状况，异种免疫疾病或状况，癌症，包括淋巴瘤，以及炎症性疾病或状况。
• ANTI-VIRAL COMPOUNDS
  申请人：ABBVIE INC.

  公开号：US20140213595A1

  公开（公告）日：2014-07-31

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  本发明描述了一种抑制丙型肝炎病毒（“HCV”）复制的有效化合物。本发明还涉及制备这些化合物的方法、包含这些化合物的组合物以及使用这些化合物治疗HCV感染的方法。
• Triazoles for the treatment of demyelinating dieases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US10766869B2

  公开（公告）日：2020-09-08

  The invention relates to triazole compounds of formula I and I′ or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

  本发明涉及式 I 和 I′ 的三唑化合物或其药学上可接受的盐类，可用作脱髓鞘疾病的调节剂： 本发明还提供了包含本发明化合物的药学上可接受的组合物、使用组合物的方法及其试剂盒，用于治疗各种脱髓鞘和神经退行性疾病，包括多发性硬化症。